Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
At least 11 killed in South Africa mass shooting - 2Figuring out the Business venture Code: The Response to Building an Effective Startup
- 3Portugal among EU countries with the most people working close to 50 hours a week
- 4The most effective method to Go with Informed Choices on Vehicle Leases
- 5A soft launch, an unfollow and a lot of questions: Breaking down the 'Summer House' romance blowing up group chats
- From Fledgling to Master: Self-awareness in a Side interest
- The Fate of Gaming: 5 Energizing Advancements Not too far off
- 6 Tire Brands Reasonable for Seniors
- 2025 Arctic League telethon raises more than $39k
- The top astronomical discoveries of 2025
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.
- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- Floods, Landslides Triggered By Heavy Rain In Afghanistan Leave 77 Dead In 10 days, Authorities Say
